{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:11Z","timestamp":1787021411752,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence-based guidelines for follow-up treatment of American Joint Committee on Cancer (AJCC) stages 1B to 2C melanoma patients are lacking. The MELanoma FOllow-up study is an international phase 3 randomized trial, and the 3-year interim data were recently reported from the Netherlands. The study was undertaken concurrently with a British cohort for comparison and validation of the Dutch study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study enrolled and stratified 207 patients by AJCC stage. The conventional schedule group (CSG;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009103) cohort was reviewed as per UK guidelines. The experimental schedule group (ESG;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009104) cohort was reviewed in a reduced-frequency nurse-led, consultant-supervised clinic. Quality of life (QoL) was measured at baseline (T1), a 1\u00a0year (T2), and at 3\u00a0years (T3) using the State-Trait Anxiety Inventory, the Cancer Worry Scale, the Impact-of-Event Scale, and the Mental and Physical Component scales (PCS\/MCS) of the RAND-36.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 207 QoL questionnaires, 170 (82.1%) were completed at T3. Both cohorts expressed high satisfaction (&gt;\u200993%) with their regimens. At T3, no significant group effect was found on any patient-reported outcome measures scores, indicating no QoL difference between the follow-up protocols. Recurrence had developed in 33 patients Conventional follow-up (CFU), 16 [15.5%]; Experimental follow-up (EFU), 17 [16.3%]. Self-examination was the method of detection for 12 ESG patients (70.6%) and 11 CSG patients (68.8%). The melanoma-specific survival was identical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The UK 3-year data were consistent with the previous Dutch report. The reduced follow-up strategy was shown to be safe, with significant resource usage benefits for national cancer services. Patient anxiety levels were not increased by a less-intensive follow-up regimen, and acceptance was high. The study data indicate that patient self-examination is very effective for recurrence detection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-020-08758-2","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T15:02:23Z","timestamp":1593874943000},"page":"4109-4119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years"],"prefix":"10.1245","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc D.","family":"Moncrieff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Garioch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Bastiaannet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josette E. H. M.","family":"Hoekstra-Weebers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"8758_CR1","unstructured":"Melanoma Skin Cancer Statistics. Cancer Research UK. Published 14 May 2019. Retrieved 30 December 2019 at https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/melanoma-skin-cancer."},{"key":"8758_CR2","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","DOI":"10.3322\/caac.21409"},{"key":"8758_CR3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","volume":"36","author":"SL Wong","year":"2018","unstructured":"Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:399\u2013413.","journal-title":"J Clin Oncol"},{"key":"8758_CR4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med"},{"key":"8758_CR5","doi-asserted-by":"publisher","unstructured":"Peach H, Board R, Cook M, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: a UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73(1):36\u201342. https:\/\/doi.org\/10.1016\/j.bjps.2019.06.020.","DOI":"10.1016\/j.bjps.2019.06.020"},{"key":"8758_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjd.13403","volume":"172","author":"CG Watts","year":"2015","unstructured":"Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE. Clinical practice guidelines for identification, screening, and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol. 2015;172:33\u201347.","journal-title":"Br J Dermatol"},{"key":"8758_CR7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/bjs.6347","volume":"95","author":"AB Francken","year":"2008","unstructured":"Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008;95:1401\u20137.","journal-title":"Br J Surg"},{"key":"8758_CR8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3322\/caac.21253","volume":"65","author":"SF Shaitelman","year":"2015","unstructured":"Shaitelman SF, Cromwell KD, Rasmussen JC, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65:55\u201381.","journal-title":"CA Cancer J Clin"},{"key":"8758_CR9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1245\/s10434-017-6319-z","volume":"25","author":"RL Read","year":"2018","unstructured":"Read RL, Madronio CM, Cust AE, et al. Follow-up recommendations after diagnosis of primary cutaneous melanoma: a population-based study in New South Wales, Australia. Ann Surg Oncol. 2018;25:617\u201325.","journal-title":"Ann Surg Oncol"},{"key":"8758_CR10","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1200\/JCO.2010.34.2956","volume":"29","author":"RM Turner","year":"2011","unstructured":"Turner RM, Bell KJL, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011;29:4641\u20136.","journal-title":"J Clin Oncol"},{"key":"8758_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jso.23278","volume":"107","author":"L Rychetnik","year":"2013","unstructured":"Rychetnik L, McCaffery K, Morton RL, Thompson JF, Menzies SW, Irwig L. Follow-up of early-stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. J Surg Oncol. 2013;107:463\u20138.","journal-title":"J Surg Oncol"},{"key":"8758_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/edm.10.38","volume":"5","author":"MJ Speijers","year":"2010","unstructured":"Speijers MJ, Francken AB, Hoekstra-Weebers JE, Bastiaannet E, Kruijff S, Hoekstra HJ. Optimal follow-up for melanoma. Expert Rev Dermatol. 2010;5:461\u201378. https:\/\/doi.org\/10.1586\/edm.10.38.","journal-title":"Expert Rev Dermatol"},{"key":"8758_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ejca.2015.01.007","volume":"51","author":"E Livingstone","year":"2015","unstructured":"Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany: results of a multicentre and longitudinal study. Eur J Cancer. 2015;51:653\u201367.","journal-title":"Eur J Cancer"},{"key":"8758_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1470-2045(05)70283-7","volume":"6","author":"AB Francken","year":"2005","unstructured":"Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608\u201321.","journal-title":"Lancet Oncol"},{"key":"8758_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1245\/s10434-007-9347-2","volume":"14","author":"AB Francken","year":"2007","unstructured":"Francken AB, Shaw HM, Accortt NA, Soong S-J, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924\u201333.","journal-title":"Ann Surg Oncol"},{"key":"8758_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.soc.2014.12.012","volume":"24","author":"NM Rueth","year":"2015","unstructured":"Rueth NM, Cromwell KD, Cormier JN. Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am. 2015;24:359\u201377.","journal-title":"Surg Oncol Clin N Am"},{"key":"8758_CR17","doi-asserted-by":"crossref","unstructured":"Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8\u00a0mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25:894\u2013902.","DOI":"10.1245\/s10434-017-6325-1"},{"key":"8758_CR18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07825-7","author":"EA Deckers","year":"2020","unstructured":"Deckers EA, Hoekstra-Weebers JEHM, Damude S, et al. The MELFO study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients: results after 3 years. Ann Surg Oncol. 2020;27:1407\u201317. https:\/\/doi.org\/10.1245\/s10434-019-07825-7.","journal-title":"Ann Surg Oncol"},{"key":"8758_CR19","doi-asserted-by":"crossref","unstructured":"Damude S, Hoekstra-Weebers JEHM, Francken AB, ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients: results after 1\u00a0year. Ann Surg Oncol. 23:2762\u201371.","DOI":"10.1245\/s10434-016-5263-7"},{"key":"8758_CR20","unstructured":"Melanoma: assessment and management\/Guidance and guidelines\/NICE. Retrieved 22 November 2018 at https:\/\/www.nice.org.uk\/guidance\/ng14."},{"key":"8758_CR21","unstructured":"Spielberger CD, Gorsuch RL, Lushene R. Manual for the State-Trait Anxiety Inventory for adults: instruments (adult form) and scoring guide. Menlo Park,\nCA: Mind Garden; 2013."},{"key":"8758_CR22","doi-asserted-by":"publisher","DOI":"10.1037\/t29446-000","author":"C Lerman","year":"2014","unstructured":"Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Cancer worry measures. PsycTESTS Dataset. 2014. https:\/\/doi.org\/10.1037\/t29446-000.","journal-title":"PsycTESTS Dataset"},{"key":"8758_CR23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00520-015-2808-4","volume":"24","author":"JAE Custers","year":"2016","unstructured":"Custers JAE, Gielissen MFM, Janssen SHV, de Wilt JHW, Prins JB. Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer. 2016;24:555\u201362.","journal-title":"Support Care Cancer"},{"key":"8758_CR24","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1097\/ncc.0b013e3182813a17","volume":"37","author":"JAE Custers","year":"2014","unstructured":"Custers JAE, van den Berg SW, van Laarhoven HWM, Bleiker EMA, Gielissen MFM, Prins JB. The cancer worry scale. Cancer Nurs. 2014;37:E44\u2013E50. https:\/\/doi.org\/10.1097\/ncc.0b013e3182813a17.","journal-title":"Cancer Nurs"},{"key":"8758_CR25","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00520-013-1793-8","volume":"21","author":"B Yanez","year":"2013","unstructured":"Yanez B, Garcia SF, Victorson D, Salsman JM. Distress among young adult cancer survivors: a cohort study. Support Care Cancer. 2013;21:2403\u20138. https:\/\/doi.org\/10.1007\/s00520-013-1793-8.","journal-title":"Support Care Cancer"},{"key":"8758_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006842-197905000-00004","volume":"41","author":"M Horowitz","year":"1979","unstructured":"Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209\u201318.","journal-title":"Psychosom Med"},{"key":"8758_CR27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","volume":"33","author":"RD Hays","year":"2001","unstructured":"Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350\u20137.","journal-title":"Ann Med"},{"key":"8758_CR28","doi-asserted-by":"crossref","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. Routledge, 2013:20\u20136.","DOI":"10.4324\/9780203771587"},{"key":"8758_CR29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pon.3060","volume":"22","author":"L Rychetnik","year":"2013","unstructured":"Rychetnik L, McCaffery K, Morton R, Irwig L. Psychosocial aspects of post-treatment follow-up for stage I\/II melanoma: a systematic review of the literature. Psychooncology. 2013;22:721\u201336.","journal-title":"Psychooncology"},{"key":"8758_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1245\/s10434-017-6321-5","volume":"25","author":"K Shirai","year":"2018","unstructured":"Shirai K, Wong SL. Melanoma surveillance strategies: different approaches to a shared goal. Ann Surg Oncol. 2018;25:583\u20134.","journal-title":"Ann Surg Oncol"},{"key":"8758_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejso.2007.06.004","volume":"34","author":"AB Francken","year":"2008","unstructured":"Francken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol. 2008;34:587\u201392.","journal-title":"Eur J Surg Oncol"},{"key":"8758_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-7682-6-8","volume":"6","author":"A K\u00f6rner","year":"2013","unstructured":"K\u00f6rner A, Coroiu A, Martins C, Wang B. Predictors of skin self-examination before and after a melanoma diagnosis: the role of medical advice and patient\u2019s level of education. Int Arch Med. 2013;6:8.","journal-title":"Int Arch Med"},{"key":"8758_CR33","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ejso.2017.06.008","volume":"43","author":"S Damude","year":"2017","unstructured":"Damude S, Hoekstra-Weebers JEHM, van Leeuwen BL, Hoekstra HJ. Melanoma patients\u2019 disease-specific knowledge, information preference, and appreciation of educational YouTube videos for self-inspection. Eur J Surg Oncol. 2017;43:1528\u201335.","journal-title":"Eur J Surg Oncol"},{"key":"8758_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351.","journal-title":"Lancet Oncol"},{"key":"8758_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5:187\u201394.","journal-title":"JAMA Oncol"},{"key":"8758_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T19:04:18Z","timestamp":1625339058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["8758"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08758-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}